Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492218 | 1.00 | GLI1 (0.36) | GLI1EPHX1BCHEDPP4MAPT | |
| SCHEMBL8181948 | 1.00 | GLI1 (0.36) | GLI1EPHX1BCHEDPP4MAPT | |
| SCHEMBL14340784 | 0.89 | EPHX1 (0.41) | GLI1EPHX1BCHECTSBCTSS | |
| SCHEMBL21545609 | 0.89 | GLI1 (0.41) | GLI1BCHEDPP4MAPTMME | |
| SCHEMBL197080 | 0.89 | — | — | |
| SCHEMBL13841189 | 0.86 | DPP4 (0.35) | GLI1EPHX1BCHEDPP4MAPT | |
| SCHEMBL24511671 | 0.80 | GLI1 (0.36) | GLI1BCHEDPP4MMECYP2D6 | |
| SCHEMBL2950685 | 0.80 | LMNA (0.43) | GLI1BCHEDPP4MMEHTT | |
| SCHEMBL9128397 | 0.80 | GLI1 (0.36) | GLI1BCHEDPP4MMECYP2D6 | |
| SCHEMBL2950683 | 0.80 | LMNA (0.43) | GLI1BCHEDPP4MMEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2022081912-A2 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-3782994-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3390395-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10039843-B2 | Paramagnetic solid lipid nanoparticles (pSLNs) containing metal amphiphilic complexes for MRI | BRACCO IMAGING S.P.A. (IT) | 2018-08-07 | — | — | US | disclosed |
| WO-2017103611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | REDX PHARMA PLC (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-20150258221-A1 | Paramagnetic Solid Lipid Nanoparticles (pSLNs) Containing Metal Amphiphilic Complexes For MRI | BRACCO IMAGING S.P.A. (IT) | 2015-09-17 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150037261-A1 | New Class Of Diazepine Derivative Chelating Agents And Complexes With Paramagnetic Metals Thereof As MRI Contrast Agents | BRACCO IMAGING S.P.A. (IT) | 2015-02-05 | — | — | US | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | GLI1 4087/4885EPHX1 829/4885BCHE 4331/4885 |
| US-20150037261-A1 | New Class Of Diazepine Derivative Chelating Agents And Complexes With Paramagnetic Metals Thereof As MRI Contrast Agents | BAZ2A, BAZ2B, BAZ1A | GLI1 3145/4885EPHX1 3360/4885BCHE 2645/4885 |
| US-10039843-B2 | Paramagnetic solid lipid nanoparticles (pSLNs) containing metal amphiphilic complexes for MRI | PLIN3, PEX3, SLC39A3 | GLI1 1430/4885EPHX1 3064/4885BCHE 1047/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | GLI1 89/4885EPHX1 4387/4885BCHE 4534/4885 |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | MC5R, MC4R, OPRD1 | GLI1 4420/4885EPHX1 1192/4885BCHE 2429/4885 |
| US-20150258221-A1 | Paramagnetic Solid Lipid Nanoparticles (pSLNs) Containing Metal Amphiphilic Complexes For MRI | PLIN3, PEX3, SLC39A3 | GLI1 1430/4885EPHX1 3064/4885BCHE 1047/4885 |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | GLI1 1318/4885EPHX1 1204/4885BCHE 3960/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | GLI1 89/4885EPHX1 4387/4885BCHE 4534/4885 |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | GLI1 817/4885EPHX1 2219/4885BCHE 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.